FHTX shares ARID1B, CBP, EP300 pipeline updates; exhibits filed

Rhea-AI Filing Summary

Foghorn Therapeutics (FHTX) filed an 8-K announcing pipeline updates for its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs. On October 30, 2025, the company hosted a conference call and webcast to review these updates, and furnished the related presentation as Exhibit 99.1 under Regulation FD.

Foghorn also issued a press release on the same date, attached as Exhibit 99.2 and incorporated by reference. The furnished materials are not deemed filed for liability purposes under Section 18 of the Exchange Act. The disclosure includes customary forward-looking statements language referencing clinical trials, product candidates, and risk factors in the company’s most recent Form 10-K.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000182246200018224622025-10-302025-10-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 8-K

________________________________________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2025

________________________________________________________________________________________________

Foghorn Therapeutics Inc.

(Exact name of registrant as specified in its charter)

________________________________________________________________________________________________

Delaware

001-39634

47-5271393

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

500 Technology Square, Ste 700

Cambridge,

MA

02139

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (617) 586-3100

Not Applicable

(Former name or former address, if changed since last report)

________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

FHTX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 30, 2025, Foghorn Therapeutics Inc. (the “Company”) is hosting a conference call and webcast to review pipeline updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs. A copy of the presentation from the conference call and webcast is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01    Other Events.

On October 30, 2025, the Company issued a press release announcing pipeline updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs.

A copy of the Company’s press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.			Description
99.1			Webcast Presentation dated October 30, 2025
99.2			Press release issued on October 30, 2025

Forward-Looking Statements.

This Current Report on Form 8-K contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this Current Report speaks only as of the date on which it is made.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			FOGHORN THERAPEUTICS INC.
			By:						/s/ Kristian Humer
									Kristian Humer
									Chief Financial Officer

Date: October 30, 2025

FAQ

What did Foghorn Therapeutics (FHTX) disclose in its 8-K?

The company announced pipeline updates for its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs and shared related materials.

When were the updates shared by Foghorn Therapeutics (FHTX)?

On October 30, 2025, via a conference call, webcast, and a press release.

Which exhibits accompany the FHTX 8-K filing?

Exhibit 99.1 is the webcast presentation and Exhibit 99.2 is the press release, both dated October 30, 2025.

Are the furnished materials considered filed under the Exchange Act?

No. The Item 7.01 information, including Exhibit 99.1, is furnished and not deemed filed under Section 18.

Which programs were highlighted by Foghorn Therapeutics (FHTX)?

Selective ARID1B degrader, Selective CBP degrader, and Selective EP300 degrader programs.

Does the 8-K include forward-looking statements?

Yes. It includes forward-looking statements regarding clinical trials and product candidates, with risk factors referenced from the latest Form 10-K.